Clinical Trial Update: A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin [Phase 2]

View source ↗

Summary

Phase 2 dose-response study comparing dabigatran etexilate to warfarin in non-valvular atrial fibrillation completed; results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Dabigatran etexilate (Dabigatran etexilate)
• Warfarin (warfarin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Atrial Fibrillation | Phase 2 | Status: COMPLETED | Results posted: 2010-12-17